Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease [PDF]
Frontiers in ImmunologyBackground and aimsFavourable clinical data were published on the efficacy of CT-P13, the first biosimilar of infliximab (IFX), in pediatric inflammatory bowel disease (IBD); however, few studies have compared the effect on endoscopic healing (EH) and ...
Eun Sil Kim +31 more
doaj +6 more sources
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]
Therapeutic Advances in Gastroenterology, 2017 Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Joana V Afonso +2 more
exaly +8 more sources
Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab [PDF]
Gut and Liver, 2023 Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park +9 more
doaj +6 more sources
Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13 [PDF]
Journal of Rheumatic DiseasesObjective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Yongbum Kim +5 more
doaj +3 more sources
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13) [PDF]
BMJ Open Gastroenterology, 2023 Background We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre.Methods All adult patients with ...
Alaa Alakkari +6 more
doaj +3 more sources
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis [PDF]
BMC GastroenterologyBackground Since 2015, an infliximab biosimilar, CT-P13, has been approved for commercial use in many countries, easing the economic burden borne by society and patients.
Xinyue Hu +6 more
doaj +3 more sources
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants [PDF]
Clinical and Translational ScienceCT‐P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation.
Ye Chan Park +6 more
doaj +3 more sources
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters [PDF]
mAbs, 2021 The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological
HoUng Kim +16 more
doaj +3 more sources
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) [PDF]
Frontiers in Medicine, 2021 Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK). Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory diseases.
Corrado Campochiaro +16 more
doaj +3 more sources
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study [PDF]
Biomedicines, 2022 Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation.
Jose M. Huguet +11 more
doaj +3 more sources